Economy

Most Recent Analysts Ratings Horizon Pharma plc (HZNP)

Some buy side analysts are also providing their Analysis on Horizon Pharma plc, where 4 analysts have rated the stock as Strong buy, 6 analysts have given a Buy signal, 2 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. The relative volume of the stock is 0.53, while its market cap is $2.25 Billion. It has underperformed by 44.83% the S&P500. The CCI technical indicator can be used to help determine if a stock is overbought or oversold. To make the technical rating meaningful, the moving averages are also compared to each other.

05/08/2017 - Horizon Pharma, Inc. had its "outperform" rating reiterated by analysts at Cowen.

07/14/2016 - Horizon Pharma, Inc. had its "buy" rating reiterated by analysts at Brean Capital. The firm has "Buy" rating by Mizuho given on Monday, December 14.

Colliers International Group Inc.is engaged in the provision of commercial real estate services. Broadfin Capital Llc bought 3.06 million shares as the company's stock declined 38.11% while stock markets rallied. It has a 26.11 P/E ratio. The Company's divisions include Americas; Europe, Middle East and Africa; Asia Pacific, and Corporate. Entercom Communications Corp. (ETM) has declined 15.65% since October 20, 2016 and is downtrending. About 1.20 million shares traded.

Investors sentiment decreased to 0.92 in Q2 2017. Its down 0.10, from 1.02 in 2017Q1. Amalgamated Bank grew its stake in shares of Horizon Pharma PLC by 4.8% in the 2nd quarter. 130.94 million shares or 1.72% less from 133.24 million shares in 2017Q1 were reported. 127,000 were reported by State Of Wisconsin Board. Cornerstone has 847 shares. Finally, Cantor Fitzgerald reissued a "buy" rating and issued a $17.00 price objective on shares of Horizon Pharma PLC in a research report on Tuesday, September 26th. Deerfield Mngmt Co accumulated 9.00 million shares. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%.

Horizon Pharma PLC (NASDAQ:HZNP) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Tuesday, October 10th. 162,900 are owned by Tekla Cap Management Limited Liability.

TRADEMARK VIOLATION NOTICE: "Horizon Pharma PLC (HZNP) Rating Increased to Buy at ValuEngine" was originally posted by BBNS and is owned by of BBNS. Bank of Montreal Can lifted its position in Horizon Pharma PLC by 16.3% during the second quarter. BidaskClub raised Horizon Pharma PLC from a hold rating to a buy rating in a research report on Saturday, June 24th. Geode Capital Management Limited Com has invested 0.01% in Horizon Pharma PLC (NASDAQ:HZNP).

More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) were released by: Globenewswire.com and their article: "Horizon Pharma plc Appoints Pascale Witz and James Shannon, MD to Board of ..." published on August 03, 2017 as well as Globenewswire.com's news article titled: "Horizon Pharma plc Announces Michelle Parsons as a 2017 Healthcare ..." with publication date: May 11, 2017. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. It now has negative earnings.

Since May 10, 2017, it had 1 buying transaction, and 0 insider sales for $94,800 activity. Another trade for 10,000 shares valued at $94,800 was bought by GREY MICHAEL G.

In case of Revenue Estimates, 10 analysts have provided their consensus Average Revenue Estimates for Horizon Pharma plc as 259.74 Million. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The rating was maintained by Citigroup with "Neutral" on Tuesday, August 9. The rating was initiated by Goldman Sachs with "Buy" on Thursday, December 17. They now have a Dollars 18 price target on the stock.

10/22/2015 - Horizon Pharma, Inc. had its "buy" rating reiterated by analysts at JMP Securities. The company was maintained on Tuesday, February 28 by Mizuho. The Average True Range is an investor tool used to measure stock volatility.



Like this

Latest


21 October 2017
IPG Photonics Corporation (NASDAQ:IPGP) Trading Up - Insider Trading Activity
Central Retail Bank Trust holds 22,515 shares or 1.13% of its portfolio. 175,409 shares of the company were exchanged. The Company sells its products globally to original equipment manufacturers (OEMs), system integrators and end users.

21 October 2017
Has $8.36 Million Position in General Mills, Inc. (GIS)
Bruce Kovner decreased its stake in General Mls Inc ( GIS ) by 89.5% based on its latest 2017Q2 regulatory filing with the SEC. General Mills now has $29.57 billion valuation. (NYSE: GIS ) on Thursday, September 21 with "Sector Perform" rating.

21 October 2017
Hikari Tsushin Inc. Buys Shares of 98800 Diamond Offshore Drilling, Inc. (DO)
The percentage of shares being held by the company management was 6.84% while institutional stake was 81.78%. The stock climbed 26.52 percent over the past quarter, while surged 0.54 percent over the past six months.

21 October 2017
Credit Suisse Maintains Rating And Raises Price Target On Danaher Corporation (DHR)
Following the sale, the insider now directly owns 45,748 shares of the company's stock, valued at approximately $3,790,679.28. TRADEMARK VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal.

21 October 2017
Parsley Energy, Inc. (PE) Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research lowered SM Energy from a "hold" rating to a "sell" rating in a research report on Wednesday, July 19th. The business had revenue of $284.94 million during the quarter, compared to analyst estimates of $299.12 million.

21 October 2017
UBS AG Trims Holly Energy Partners, LP (HEP) Target Price to $36.00
Silvercrest Asset Mgmt Llc holds 0.11% or 236,586 shares. 205648 shares were traded on Spectra Energy Partners, LP's last session. The Firm operates through divisions, including pipelines and terminals segment and a refinery processing unit segment.

21 October 2017
Ericsson reports big loss as it struggles against rivals
Sweden's Ericsson (ERIC) reported Friday that its third-quarter net loss was 4.3 billion Swedish kronor, wider than loss of 0.2 billion kronor a year ago.

21 October 2017
Stocks Securing Modest Gains: The Charles Schwab Corporation (NYSE:SCHW)
West Oak Cap Limited Liability Com holds 0% of its portfolio in United Technologies Corporation (NYSE:UTX) for 4,812 shares. The company has market cap of $484.13 million. $226,739 worth of stock was sold by SIMONCIC RICHARD J on Monday, May 22.

21 October 2017
1 dead, 6 injured as police opens fire on protestors
The SP said, the police personnel had to resort to firing in the air after they could not disperse the crowd with batons. The protesters were fired upon in Samastipur district, about 84 km northeast of Patna , the capital city of Bihar.

21 October 2017
Chandler Parsons Finds Booing From Memphis Crowd 'Tasteless'
Memphis fans won't have to wait long to answer Parsons' comments, as the team hosts the Golden State Warriors on Saturday. When he did play, Parsons was far from the player Memphis believed it was getting when it gave him the max.



Recommended